Biocompatible Materials for the Human Body
The U.S. market for biocompatible materials is valued at $ 22.2 billion in 2007 and is expected to grow with a compound annual growth rate (CAGR) of 6.9% to reach $30.9 billion in 2012.
Tissue replacements constitute the largest segment with a value of nearly $11.7 billion in 2007. This represents 52% of the total biomaterials market value. The tissue replacements will grow at a CAGR of 6.6% to reach over $16 billion in 2012.
The smallest segment of the biomaterials market is biocompatible surface coatings with a value of $2.6 billion in 2007. This segment is expected to grow with a CAGR of 5.7% to $3.4 billion by 2012.
A biocompatible material or a biomaterial is any natural or synthetic substance that incorporates or integrates into a patient's body. The role of the biomaterial may be to perform, supplement, or replace a biological function that is attenuated or lost.
The goal of this report is to assess the current market for biocompatible materials including medical devices, tissue replacements, and surface coatings.
This report provides a complete overview of recent developments in each major sector of the biomaterials market. It also outlines the significant medical applications of each technology; the major market players; recent patents; and emerging technologies in implantable medical devices, advanced tissue replacements, and biocompatible surface coatings.
SCOPE OF STUDY
This report contains:
- An examination of the supporting products that have enhanced imaging at the chemical level (reagents and contrast media) and at the analysis level (software tools and image management)
- The U.S. markets for medical devices, tissue replacements, and surface coating biomaterials for a variety of biomaterials categories including metals, ceramics, polymers, and natural materials
- Assessment of the market for specific medical applications including orthopedic surgery, cardiovascular surgery and care, wound management, dentistry, urology, gastrointestinal surgery, ophthalmic care as well as plastics and reconstructive surgery
- A review of important technology and a discussion of patents in the past few decades
- Profiles of all the major companies in the industry.
This report has been assembled following an in-depth analysis of primary and secondary data. Primary research was conducted via telephone interviews with industry professionals, research scientists, physician-researchers, and laboratory heads to discover the most recent developments in their fields of interest. Secondary data was collected via a comprehensive search of the scientific, peer-reviewed literature, clinical trial reports and databases, industry trade media, company websites, annual reports, and industry press releases.
The market assessments provided have been assembled based on publicly available information from January 2002 up to and including 2007-01-15. The base year for this report is 2007 and forecast data are provided through 2012. In many cases, figures for 2006 were not yet released and in these cases figures were extrapolated from 2006 statistics, first quarter projections for 2007, and historical trends between 2002 and 2007. Market figures are based on current (2007) dollars and inflation is not computed into the projection figures.
Amy Brock, Ph.D. has over 10 years of research experience working at the interface of the biological sciences, bioengineering, and biophysics. Trained at the Massachusetts Institute of Technology and Harvard University, she holds a B.S. and Ph.D. in biomedical science. She is the author of Pharmacogenomics: New Technologies in the Development of Personalized Therapies, Kinase Inhibitors and Genetic Diseases and Medical Imaging.
The U.S. biocompatibles market in 2003 is expected to reach $8.2 billion in sales
This market will grow at a 7.7% AAGR (average annual growth rate) through 2008 to reach $11.9 billion.
Polymer consumption, of which 80% are PVCs, will grow at a 7.9% AAGR.
Titanium, stainless steel and other metals will reach $212.8 million in 2008.
Nanotechnology is expected to yield new drug delivery products, sensors and high-performance biocompatible materials that will allow "smart" rejection resistant implants.